EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study - EXTEND

GlaxoSmithKline Research and Development Limited0 个研究点目标入组 200 人开始时间: 2006年9月4日最近更新: 2016年5月2日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Subject has signed and dated a written informed consent.
•2. Adults (at least 18 years) diagnosed with ITP according to the American Society for Hematology/British Committee for Standards in Haematology (ASH/BCSH) guidelines. In addition, the peripheral blood smear should support the diagnosis of ITP with no evidence of other disease causative of thrombocytopenia (e.g., pseudo thrombocytopenia, myelofibrosis). The physical examination should be normal or at least not show signs suggestive of any disease likely to be associated with thrombocytopenia.
•3. Prior randomization and completion of treatment and follow up periods in an ITP study of eltrombopag (e.g., TRA100773 or TRA102537/RAISE).
•4. Subjects previously enrolled in Study TRA100773 must have completed the prescribed follow-up ophthalmic assessment at 6 months without observation of an ocular event of clinical concern.
•5. Subjects previously enrolled in TRA102537/RAISE must have completed the treatment and follow-up periods as defined in that protocol.
•6. Subject experienced no eltrombopag-related SAE or other drug intolerance on prior eltrombopag study even if resolved; subjects discontinued from previous study due to toxicity will not be eligible unless they received placebo.
•7. Subject has no intercurrent medical event, including evidence of new cataract formation or any thrombosis.
•8. Ophthalmic examinations performed during prior studies have not identified ocular events of clinical concern that changed from the screening visit (baseline eye assessment).
•9. Subjects must have either initially responded (platelet count > 100,000/µL) to a previous ITP therapy or have had a bone marrow biopsy consistent with ITP within 3 years to rule out myelodysplasia or other causes of thrombocytopenia.
•10. Previous therapy for ITP with immunoglobulins (IVIg and anti-D), and cyclophosphamide must have been completed at least 4 weeks prior to Day 1. Treatment with rituximab must have been completed at least 12 weeks prior to Day 1 of study treatment. Subjects who have had a splenectomy must have had the procedure performed at least 4 weeks prior to study Day 1.
•11. Subjects treated with corticosteroids must be receiving a dose that has been stable (dose change of +/- 5% is acceptable) for at least 1 month prior to Day 1 of study. Subjects treated with cyclosporin A, mycophenolate mofetil, azathioprine or danazol must be receiving a dose that has been stable (dose change of +/- 5% is acceptable) for at least 3 months prior to Day 1 of study treatment.
•12. Normal prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT), no history of hypercoagulable state.
•13. A complete blood count (CBC), within the reference range (including differential not indicative of a disorder other than ITP), with the following exceptions:
•Hemoglobin: Subjects with hemoglobin levels between 10.0 g/dL and the lower limit of normal are eligible for inclusion, if anemia is clearly attributable to ITP (i.e., excessive blood loss).
•ANC greater than 1500/microL (1.5 x 109/L) is required for inclusion (elevated WBC/ANC due to steroid treatment is acceptable).
•14. The following clinical chemistries must be within the normal reference range: creatinine, ALT, AST, total bilirubin, total albumin and alkaline phosphatase.
•15. Subject is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must either be of non-childbearing poten

排除标准

•1. Any clinically relevant abnormality, other than ITP, identified on the screening examination, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another diagnosis.
•2. History of malignancy. NOTE: Patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma, are eligible.
•3. History of arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism).
•4. Any prior history of arterial or venous thrombosis AND at least two of the following risk factors: Factor V Leiden, hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer.
•5. Pre-existing cardiac disease (including congestive heart failure, and arrhythmia requiring treatment), or clinically significant findings on resting 12-lead ECG at screening.
•6. Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotrophin (beta-hCG) pregnancy test) at screening or pre-dose on Day 1.
•7. History of alcohol/drug abuse.
•8. Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
•9. Subject treated with aspirin, aspirin-containing compounds, salicylates, anti-coagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for > 3 consecutive days within 2 weeks of the study start and until the end of the study.
•10. Consumption of any herbal or dietary supplements, excluding vitamin or mineral supplements, within 1 week of the study start (see Section 9.1.1. for instructions for taking calcium and vitamin supplements). Subjects that have consumed rosuvastatin or pravastatin within 1 week of the first dose of study medication and/or will require these medications during the study period.
•11. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.
•12. All subjects with secondary immune thrombocytopenia, including those with laboratory or clinical evidence of HIV infection, antiphospholipid antibody syndrome, chronic hepatitis B infection, hepatitis C virus infection, or any evidence for active hepatitis at the time of subject screening. If a potential subject has no clinical history that would support HIV infection or hepatitis infection, no further laboratory screening is necessary; however, standard medical practice would suggest further evaluation of patients who have risk factors for these infections.
•13. A subject is planning to have cataract surgery.
•14. In France, a subject is neither affiliated with nor a beneficiary of a social security category.

研究者

发起方

GlaxoSmithKline Research and Development Limited

相似试验

进行中（未招募）

不适用

EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study - EXTENDImmune thrombocytopenic purpura (ITP)

EUCTR2006-000471-14-SIGlaxoSmithKline Research and Development Limited200

进行中（未招募）

1 期

Extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial.

EUCTR2006-000471-14-SKGlaxoSmithKline Research and Development Limited400

进行中（未招募）

不适用

EUCTR2006-000471-14-NLGlaxoSmithKline Research and Development Limited200

进行中（未招募）

1 期

EUCTR2006-000471-14-GBGlaxoSmithKline Research and Development Limited302

进行中（未招募）

不适用

EUCTR2006-000471-14-FIGlaxoSmithKline Research and Development Limited400